Take the 2-minute tour ×
Biology Stack Exchange is a question and answer site for biology researchers, academics, and students. It's 100% free, no registration required.

Plateletpheresis is seperation of platelets from whole blood and putting the leukocytes and erythrocytes back into the blood.

If the person donating platelets does not have hemophilia than could a hemophilia patient get a periodic transfusion of platelets from a non-hemophiliac platelet donor so that his hemophilia is less severe whether it is hemophilia A or hemophilia B?

share|improve this question
    
Wikipedia has a nice page on clotting disorders - it shows Hemophilia isn't a defect/deficiency of platelets, but rather due to defective clotting factors in the plasma. When platelets are transfused, they have a very short half-life and are used for acute support in disorders like Bernard-Soulier syndrome –  PlaysDice May 30 at 20:55
    
but platelets are transfused along with plasma aren't they since platelets and plasma are hard to separate? If so than if someone gets a plasma transfusion with platelets which still qualifies as plateletpheresis from someone without hemophilia and the person getting the transfusion has hemophilia it should lower the bleeding from something as simple as bumping on something. –  caters May 30 at 22:08
    
Indeed, under US standards, an apheresis platelet product contains platelets in donor plasma. But hemophilliacs are typically treated using plasma-derived or manufactured ("recombinant") clotting factors since that addresses the actual underlying basis of their condition. –  PlaysDice May 31 at 3:14
    
yes I know but clotting factors are in the plasma so wouldn't it make sense that a non-hemophiliac donor of plasma if it donates blood to a hemophiliac that the clotting factors within the donor plasma would lower the risk of bleeding for much longer than those manufactured clotting factors? –  caters May 31 at 4:12
    
Plasma contains antibodies that can cause transfusion reactions, so giving bulk plasma requires cross-matching. Instead, the fraction of the plasma enriched in the clotting factor needed to complement the deficiency in hemophilia, or recombinant factor is used. Re duration of effect, in plasma the factor is at x1 concentration. A plasma fraction could be x1,000 and recombinant x100,000. In the 80s hemophiliacs in Canada got HIV from plasma fractions. Since it contains no pathogens, recombinant therapy is best. –  PlaysDice May 31 at 12:20

Your Answer

 
discard

By posting your answer, you agree to the privacy policy and terms of service.

Browse other questions tagged or ask your own question.